Open AccessSevere food allergy in children. Omalizumab as an alternative treatment to elimination diet
Author(s) -
Pena Peloche María,
Macías Miguel Hinojosa,
Cepeda Soledad Terrados,
Gimeno Pilar Berges,
Sánchez Moreno Gema Vanesa,
ÁlvarezCuesta Emilio
Publication year - 2011
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-1-s1-p55
Subject(s) - omalizumab , medicine , allergy , food allergy , elimination diet , food hypersensitivity , dermatology , pediatrics , immunology , immunoglobulin e , antibody
Results Ten patients were included, 3 patients suffered allergy to milk and 7 to egg . They had a positive SBFC or a previous history of food transgressions with reactions in the last six months. All patients received anti-IgE treatment without any significant adverse reaction. After 16 weeks, eight patients underwent to SBFC and complete tolerance was confirmed in four patients. Four patients presented a positive SBFC. All subjects reached a higher dose threshold than baseline SBFC. Two patients rejected SBFC. 6 patients with anaphylactic allergy were allocated in a specific oral tolerance induction (SOTI) with anti IgE treatment. During SOTI, only one subject experienced some mild side-effects, 2 patients successfully completed the treatment, and 4 patients still continue with their SOTI procedure without any significant reactions during in-patient administered doses or outpatient maintenance doses. Conclusions Anti-IgE therapy has proven an effective and safe measure in the treatment of the persistent and severe allergy to milk and egg, whether used as monotherapy or as an adjuvant measure to the process of desensitization to food, making it safer and faster procedure.